CN115698077A - 结合bcma的单可变结构域及抗原结合分子 - Google Patents

结合bcma的单可变结构域及抗原结合分子 Download PDF

Info

Publication number
CN115698077A
CN115698077A CN202180041402.4A CN202180041402A CN115698077A CN 115698077 A CN115698077 A CN 115698077A CN 202180041402 A CN202180041402 A CN 202180041402A CN 115698077 A CN115698077 A CN 115698077A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
single variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180041402.4A
Other languages
English (en)
Chinese (zh)
Inventor
甄子朋
谢美娟
杜秀贞
马毅敏
张兵
徐同杰
张喜全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN115698077A publication Critical patent/CN115698077A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180041402.4A 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子 Pending CN115698077A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010842501X 2020-08-20
CN202010842501 2020-08-20
PCT/CN2021/112758 WO2022037528A1 (zh) 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子

Publications (1)

Publication Number Publication Date
CN115698077A true CN115698077A (zh) 2023-02-03

Family

ID=80323414

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041402.4A Pending CN115698077A (zh) 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子

Country Status (6)

Country Link
US (1) US20230265181A1 (https=)
EP (1) EP4201960A4 (https=)
JP (1) JP7821161B2 (https=)
KR (1) KR20230045095A (https=)
CN (1) CN115698077A (https=)
WO (1) WO2022037528A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117062840A (zh) * 2021-04-15 2023-11-14 正大天晴药业集团股份有限公司 靶向bcma的多特异性抗体
WO2025098446A1 (zh) * 2023-11-07 2025-05-15 赛斯尔擎生物技术（上海）有限公司 抗bcma单域抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2406284B9 (en) * 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
IL271194B2 (en) * 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
AU2019214183B2 (en) * 2018-02-01 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
CN109942708B (zh) 2019-03-28 2021-01-05 上海科棋药业科技有限公司 一种抗bcma的单域抗体及其应用
CN109942709B (zh) 2019-04-22 2019-12-27 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
CN117062840A (zh) * 2021-04-15 2023-11-14 正大天晴药业集团股份有限公司 靶向bcma的多特异性抗体

Also Published As

Publication number Publication date
US20230265181A1 (en) 2023-08-24
JP7821161B2 (ja) 2026-02-26
EP4201960A1 (en) 2023-06-28
EP4201960A4 (en) 2024-09-04
JP2023539453A (ja) 2023-09-14
KR20230045095A (ko) 2023-04-04
WO2022037528A1 (zh) 2022-02-24

Similar Documents

Publication Publication Date Title
JP2020501531A5 (https=)
AU2016281641B2 (en) Novel PD-1 immune modulating agents
JP2021522801A5 (https=)
JP2019536430A5 (https=)
JP2020525032A5 (https=)
JPWO2019215728A5 (https=)
JP2011509245A5 (https=)
JP2024062992A5 (https=)
JP2019501883A5 (https=)
Chen et al. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
JP2021510736A5 (https=)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2020516309A5 (https=)
JP2016505556A5 (https=)
CN111201238B (zh) 产生多特异性抗体混合物及其使用方法
KR102058381B1 (ko) 인간 ｌ１ｃａｍ에 대한 인간화 항체 및 그의 제조 방법
JP2023129433A5 (https=)
WO2019196309A1 (zh) 抗pd-l1抗体及其用途
JPWO2021139777A5 (https=)
JP2021511026A5 (https=)
JP2021522303A5 (https=)
CN118076387A (zh) 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法
JPWO2020059847A5 (https=)
JP2020513759A5 (https=)
CN115698077A (zh) 结合bcma的单可变结构域及抗原结合分子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination